FGF19 and rhabdomyosarcoma: In Rhabdomyosarcoma, FGFR4-specific single-domain antibodies demonstrated a good specificity and affinity for targeting FGFR4-expressing cells and for blocking the FGF19–FGFR4–MAPK signaling axis [73].